Your browser doesn't support javascript.
loading
Unveiling the protective potential of mirabegron against thioacetamide-induced hepatic encephalopathy in rats: Insights into cAMP/PPAR-γ/p-ERK1/2/p S536 NF-κB p 65 and p-CREB/BDNF/TrkB in parallel with oxidative and apoptotic trajectories.
Hassan, Noha F; El-Ansary, Mona R; El-Ansary, Amira R; El-Saied, Mohamed A; Zaki, Omnia S.
Afiliación
  • Hassan NF; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.
  • El-Ansary MR; Department of Biochemistry, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.
  • El-Ansary AR; Department of Internal Medicine, Faculty of Medicine, Misr University for Science and Technology, Giza, Egypt.
  • El-Saied MA; Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
  • Zaki OS; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt. Electronic address: omnia.shafik@pharm.mti.edu.eg.
Biochem Pharmacol ; 229: 116504, 2024 11.
Article en En | MEDLINE | ID: mdl-39179118
ABSTRACT
Hepatic encephalopathy (HE) is one of the most prevalent and severe hepatic and brain disorders in which escalation of the oxidative, inflammatory and apoptotic trajectories pathologically connects acute liver injury with neurological impairment. Mirabegron (Mira) is a beta3 adrenergic receptor agonist with proven antioxidant and anti-inflammatory activities. The current research pointed to exploring Mira's hepato-and neuroprotective impacts against thioacetamide (TAA)-induced HE in rats. Rats were distributed into three experimental groups the normal control group, the TAA group, received TAA (200 mg/kg/day for three consecutive days) and the Mira-treated group received Mira (10 mg/kg/day; oral gavage) for 15 consecutive days and intoxicated with TAA from the 13th to the 15th day of the experimental period. Mira counteracted hyperammonemia, enhanced rats' locomotor capability and motor coordination. It attenuated hepatic/neurological injuries by its antioxidant, anti-apoptotic as well as anti-inflammatory potentials. Mira predominantly targeted cyclic adenosine monophosphate (cAMP)/phosphorylated extracellular signal-regulated kinase (p-Erk1/2)/peroxisome proliferator-activated receptor gamma (PPARγ) dependent pathways via downregulation of p S536-nuclear factor kappa B p65 (p S536 NF-κB p 65)/tumor necrosis alpha (TNF-α) axis. Meanwhile, it attenuated nuclear factor erythroid 2-related factor (Nrf2) depletion in parallel with restoring of the neuroprotective defensive pathway by upregulation of cerebral cAMP/PPAR-γ/p-ERK1/2 and p-CREB/BDNF/TrkB besides reduction of GFAP immunoreactivity. Mira showed anti-apoptotic activity through inhibition of Bax immunoreactivity and elevation of Bcl2. To summarize, Mira exhibited a hepato-and neuroprotective effect against TAA-induced HE in rats via shielding antioxidant defense and mitigation of the pathological inflammatory and apoptotic axis besides upregulation of neuroprotective signaling pathways.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tioacetamida / Encefalopatía Hepática / Apoptosis / Estrés Oxidativo / Factor Neurotrófico Derivado del Encéfalo / PPAR gamma Límite: Animals Idioma: En Revista: Biochem Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tioacetamida / Encefalopatía Hepática / Apoptosis / Estrés Oxidativo / Factor Neurotrófico Derivado del Encéfalo / PPAR gamma Límite: Animals Idioma: En Revista: Biochem Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Reino Unido